Organization | PharmAthene

PharmAthene Report issue

For profit Phase 1 Phase 2

Founded: Annapolis MD United States (2001)

Status: Acquired by Altimmune, Inc. (2017)

Organization Overview

First Clinical Trial

2005

NCT00170469

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PharmAthene, Inc. | PharmAthene UK Limited

Active Ingredients

Drugs in Phase 2 Trials (2)

aluminum hydroxide (Gaviscon) (3 trials)

rpa102 (2 trials)

Drugs in Phase 1 Trials (6)

butyrlcholinesterase, human (Recombinant) (Protexia) (1 trial)

ciprofloxacin (cipro) (1 trial)

doxycycline (vibramycin) (1 trial)

mdx-1303 (Valortim) (4 trials)

rf1v vaccine (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anthrax (Phase 2)

Hypersensitivity (Phase 1)

Plague (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial APIs: 8